Go Back
OrbiMed
OrbiMed, a New York-based venture fund established in 1989, specializes in healthcare investments from biopharmaceuticals to medical devices and diagnostics. With a diverse portfolio spanning BioTech, Pharmaceuticals, AI/ML, and more, OrbiMed has made 562 investments and achieved 212 exits. The fund, led by Partner Carl Gordon, backs companies like Aspen Neuroscience, Carrot Fertility, and Sionna Therapeutics across Seed to Series D stages. For more information, visit OrbiMed's website.
About
About
About
Bio
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Location
New York
Stage
Seed, Series A, Series B, Series C, Series D
Partner name
Carl Gordon
Bio
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Location
New York
Stage
Seed, Series A, Series B, Series C, Series D
Partner name
Carl Gordon
Fund
Fund
Fund
Fund Focus
BioTech, Medical Device, Pharmaceuticals, Healthcare, HR Tech, FemTech, Health & Wellness, Life Science, Artificial Intelligence & Machine Learning (AI/ML), Software, Food and Beverage, Mobile
Number of investments
562
Number of exits
212
Fund Type
Venture Fund
Portfolio Companies
Aspen Neuroscience, Carrot Fertility, Sionna Therapeutics, GentiBio, XtalPi, ReCode Therapeutics, Scribe Therapeutics, Entos, Q32 Bio, ACELYRIN, Cyrus Biotechnology, iECURE, Gennao Bio, Enliven Therapeutics, ArriVent Biopharma, Crown Bioscience, Pionyr Immunotherapeutics, Odyssey Therapeutics, Adicet Bio, Binx Health, Turnstone Biologics, Electra Therapeutics
OrbiMed
OrbiMed, a New York-based venture fund established in 1989, specializes in healthcare investments from biopharmaceuticals to medical devices and diagnostics. With a diverse portfolio spanning BioTech, Pharmaceuticals, AI/ML, and more, OrbiMed has made 562 investments and achieved 212 exits. The fund, led by Partner Carl Gordon, backs companies like Aspen Neuroscience, Carrot Fertility, and Sionna Therapeutics across Seed to Series D stages. For more information, visit OrbiMed's website.
About
Bio
OrbiMed is a healthcare-dedicated investment firm focusing on biopharmaceuticals to medical devices and diagnostics.
Location
New York
Stage
Seed, Series A, Series B, Series C, Series D
Partner name
Carl Gordon
Fund
Fund Focus
BioTech, Medical Device, Pharmaceuticals, Healthcare, HR Tech, FemTech, Health & Wellness, Life Science, Artificial Intelligence & Machine Learning (AI/ML), Software, Food and Beverage, Mobile
Number of investments
562
Number of exits
212
Fund Type
Venture Fund
Portfolio Companies
Aspen Neuroscience, Carrot Fertility, Sionna Therapeutics, GentiBio, XtalPi, ReCode Therapeutics, Scribe Therapeutics, Entos, Q32 Bio, ACELYRIN, Cyrus Biotechnology, iECURE, Gennao Bio, Enliven Therapeutics, ArriVent Biopharma, Crown Bioscience, Pionyr Immunotherapeutics, Odyssey Therapeutics, Adicet Bio, Binx Health, Turnstone Biologics, Electra Therapeutics